Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Pylarify Second Radioactive Imaging Drug FDA Approved for PSMA-Positive Prostate Cancer

Web Exclusives - FDA Oncology Update

On May 27, 2021, the FDA accelerated the approval of piflufolastat F-18 (Pylarify; Progenics Pharmaceuticals) injection, the second radioactive, prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging drug used for the diagnosis of suspected prostate cancer recurrence or metastasis.

Piflufolastat F-18 is indicated for PET diagnosis of PSMA-positive lesions in men with prostate cancer and suspected metastasis who are candidates for initial definitive therapy and for those with suspected prostate cancer recurrence, based on elevated serum prostate-specific antigen (PSA) levels. Last December, the FDA approved the first PSMA-targeted imaging drug, Ga-68 PSMA-11.

“Conventional imaging has significant limitations in detecting prostate cancer, both in initial staging and when the cancer has recurred or spread after initial primary treatment,” said Michael J. Morris, MD, Prostate Cancer Section Head, Genitourinary Medical Oncology, Memorial Sloan Kettering Cancer Center, and lead investigator in the CONDOR clinical trial. He noted that piflufolastat F-18 injection “can detect the spread of disease well before standard imaging and can be a transformative diagnostic tool.”

The FDA approval of piflufolastat F-18 was based on 2 prospective clinical trials that together included 593 men with prostate cancer who received 1 injection of piflufolastat F-18. The first study included 268 patients with prostate cancer who had PET or computed tomography (CT) scans after receiving piflufolastat F-18. The patients were candidates for resection of the prostate gland and pelvic lymph nodes and were at higher risk for metastasis. Among those who proceeded to surgery, metastatic cancer was confirmed by surgical pathology in the patients who had positive lesions on the piflufolastat F-18 PET scan. Having this information before surgery may spare patients from undergoing needless procedures.

The second study included 208 patients with elevated serum PSA levels after initial prostate surgery or other definitive therapy that provided evidence of recurrent prostate cancer. Before undergoing the piflufolastat F-18–based PET or CT scan, the patients had baseline conventional imaging that did not show definite metastasis. The use of piflufolastat F-18 detected at least 1 positive lesion in at least 1 body region (bone, prostate bed, pelvic lymph node, other lymph nodes, or soft tissue) in 60% of the patients.

The diagnosis of prostate cancer recurrence or metastasis was confirmed in an estimated 85% to 87% of patients (depending on the reader) with positive lesions using piflufolastat F-18–based PET scan who had correlated tissue pathology from biopsies, baseline or follow-up imaging by conventional methods, or serial PSA levels.

The most common adverse events with piflufolastat F-18 were headache, altered taste, and fatigue.

Related Items
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation
Online First published on September 8, 2023 in FDA Oncology Update
FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas
JHOP - August 2023 Vol 13, No 4 published on August 17, 2023 in FDA Oncology Update
Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
JHOP - August 2023 Vol 13, No 4 published on August 7, 2023 in FDA Oncology Update
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer
JHOP - August 2023 Vol 13, No 4 published on August 4, 2023 in FDA Oncology Update
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
JHOP - August 2023 Vol 13, No 4 published on July 28, 2023 in FDA Oncology Update
Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation
JHOP - August 2023 Vol 13, No 4 published on June 30, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.